Net debt stood at Rs 10,151 million and net debt to EBITDA at 0.91x
Granules India has announced its financial results for the quarter ended December 31, 2025.
Revenue from Operations of Q3FY26 stood at Rs 13,879 million, a growth of 22 per cent YoY driven by Finished Dosages (FD) segment in North America and Europe. The finished dosages (FD), Active Pharmaceuticals Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Peptides/ CDMO contribute 76 per cent, 11 per cent, 11 per cent and 2 per cent of revenue from operations respectively for Q3FY26.
Net debt stood at Rs 10,151 million and net debt to EBITDA at 0.91x.
Dr Krishna Prasad Chigurupati, Chairman and Managing Director, Granules India said, “Q3 has been one of our strongest quarters, reflecting disciplined execution of strategic growth initiatives and we are well positioned for sustained growth momentum. Our strong financial performance, on-going R&D investments, combined with advances in ESG stewardship and our expanding global supply footprint, reinforces our commitment to building a resilient, innovation-led pharmaceutical platform that delivers long-term value for all stakeholders.”
